Rapid cellular detection for hematologic malignancies
Flow cytometry enables direct quantification of residual malignant cells using immunophenotypic profiling. NeoGenomics delivers high-quality, flow cytometry–based MRD services built on standardized, tightly controlled staining and acquisition protocols. Results are analyzed by licensed clinical laboratory scientists and reviewed by board-certified hematopathologists for accuracy and consistency.
- MRD endpoints in hematologic trials
- Predicting relapse risk
- Monitoring post-transplant recurrence
- Measuring the depth of therapeutic response
New MRD solution
AML NanoMRD™
Transforming AML MRD: Minimal sample, maximum confidence, faster decisions.
An innovative, off-the-shelf, single-tube solution enabling precise and reliable relapse-risk assessment, deeper measurement of therapeutic response, and robust AML MRD tracking even with limited sample availability.
Earlier access to deeper clinical insights enables biopharma partners to make more informed development decisions, reduce program risk, and accelerate therapeutic development timelines.
Explore our comprehensive selection of off-the-shelf MRD assays